Galantamine alleviates inflammation and insulin resistance in patients with metabolic syndrome in a randomized trial

BACKGROUND. Metabolic syndrome (MetS) is an obesity-driven condition of pandemic proportions that increases the risk of type 2 diabetes and cardiovascular disease. Pathophysiological mechanisms are poorly understood, though inflammation has been implicated in MetS pathogenesis. The aim of this study...

詳細記述

保存先:
書誌詳細
出版年:JCI Insight
主要な著者: Consolim-Colombo, Fernanda M., Sangaleti, Carine T., Costa, Fernando O., Morais, Tercio L., Lopes, Heno F., Motta, Josiane M., Irigoyen, Maria C., Bortoloto, Luiz A., Rochitte, Carlos Eduardo, Harris, Yael Tobi, Satapathy, Sanjaya K., Olofsson, Peder S., Akerman, Meredith, Chavan, Sangeeta S., MacKay, Meggan, Barnaby, Douglas P., Lesser, Martin L., Roth, Jesse, Tracey, Kevin J., Pavlov, Valentin A.
フォーマット: Artigo
言語:Inglês
出版事項: American Society for Clinical Investigation 2017
主題:
Clinical Medicine
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5518569/
https://ncbi.nlm.nih.gov/pubmed/28724799
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.93340
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料